Koti, Madhuri - Queen's University - Department of Biomedical and Molecular Sciences

个人简介

Ph.D: University of Guelph, Canada M.V.Sc: Indian Veterinary Research Institute, India D.V.M: MAFSU, India I am a Veterinarian with Ph.D. in Molecular Immunology. Research in my lab is focused on delineating the role of tumor immune microenvironment in cancer progression and treatment response. Our long term goal is to identify genomic correlates of prognostic and predictive immune biomarkers that reflect differential pre-treatment tumour immune contexture. Identification of these biomarkers will inform decisions for individualized treatment approaches, augment design of novel immunomodulatory therapies and enhance response to conventional chemotherapies. https://bhsc.queensu.ca/faculty/madhuri-koti/

研究领域

Research in my lab focuses on anti-tumour immunity and treatment response in ovarian and prostate cancers. Major themes and areas of research: https: Role of Type I Interferon pathways in sensitivity or resistance to chemotherapy in ovarian cancer using cancer cell lines, in vivo mouse models and patient derived material. Immuno-genomic studies to delineate genetic correlates of intra-tumour immune diversity and association with intrinsic and acquired resistance to therapy. Role of cancer cell intrinsic genetic events and their association with distinct immune microenvironment states in prostate cancer. Development of improved non-invasive immune monitoring approaches towards thier application as prognostic and predictive indicators for personalized treatment approaches in cancer.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Katrina Au, Cécile Le Page, Runhan Ren, Liliane Meunier, Kathrin Tryshkin, Nichole Peterson, Jennifer Kendall-Dupont, Timothy Childs, Julie-Ann Francis, Charles H Graham, Andrew B. Craig, Jeremy A. Squire, Anne-Marie Mes-Masson, and Madhuri Koti*. (2016). STAT1 associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. The Journal of Pathology: Clinical Research. PMID: 27917296 Runhan Ren, Madhuri Koti, Thomas Hamilton, Charles H. Graham, Jasmir G. Nayak, Jas Singh, Darrel E. Drachenberg, D. Robert Siemens. (2016). A primer on tumour immunology and prostate cancer immunotherapy. Can Urol Assoc J. 10 (1-2). PMID: 26977209 Madison Black, Ivraym Barsoum, Tiziana Cotechini, Peter Truesdell, D. Robert Siemens, Madhuri Koti, Andrew Craig, Charles Graham. (2016) Activation of the PD-1/PD-L1 immune checkpoint confers chemoresistance and promotes tumor metastasis. Oncotarget. Feb 7. doi: 10.18632/oncotarget.7235. PMID: 26859684 Katrina Au, Juliana Josahikan, Julie-Ann Francis, Jeremy A. Squire, Madhuri Koti* (2015). Current state of biomarkers in ovarian cancer prognosis. Future Oncology. Dec 11 (23); 3187-95. PMID: 26551891 Madhuri Koti*, Alex Siu, Isabelle Clement, Mallikarjun Bidarimath, Gulisa Turashvilli, Andrew Edwards, Anne-Marie Mes Masson, Jeremy A. Squire. (2015). A distinct pre-existing inflammatory tumor microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. British Journal of Cancer. March 31; 112, 1215-1222. PMID: 26695556 Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res. 2014 Dec 15;74(24):7185-90. PMID: 25344227. Madhuri Koti, Surinder S. Saini, Ashish Sachan and Azad K. Kaushik. Engineered Bovine Antibodies in the Development of Novel Therapeutics, Immunomodulators and Vaccines. Antibodies. 2014. 3, 205-214; doi:10.3390/antib3020205. http://www.mdpi.com/2073-4468/3/2/205. Jeff W Martin, Susan Chilton-MacNeill, Madhuri Koti, Andre J van Wijnen, Jeremy A Squire, Maria Zielenska. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLoS One. 2014 May 16;9(5). PMID: 24835790. Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer. 2013 Nov 16;13:549. PMID: 24237932. Geraci J, Dharsee M, Nuin P, Haslehurst A, Koti M, Feilotter HE, Evans K. Exploring high dimensional data with Butterfly: a novel classification algorithm based on discrete dynamical systems. Bioinformatics. 2014 Mar 1;30(5):712-8. PMID: 24149051. Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012 Mar 19;12:91. PMID: 22429801. Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet. 2011 Oct;204(10):525-35. PMID: 22137482. Koti M, Kataeva G, Kaushik AK. A single point mutation in framework region 3 of heavy chain affects viral neutralization dynamics of single-chain Fv against bovine herpes virus type 1. Vaccine. 2011 Oct 19;29(45):7905-12. PMID: 21872632. Koti M, Kataeva G, Kaushik AK. Novel atypical nucleotide insertions specifically at VH-DH junction generate exceptionally long CDR3H in cattle antibodies. Mol Immunol. 2010 Jul;47(11-12):2119-28. PMID: 20435350. Koti M, Farrugia W, Nagy E, Ramsland PA, Kaushik AK. Construction of single-chain Fv with two possible CDR3H conformations but similar inter-molecular forces that neutralize bovine herpesvirus 1. Mol Immunol. 2010 Feb;47(5):953-60. PMID: 20006385. Kaushik AK, Kehrli ME Jr, Kurtz A, Ng S, Koti M, Shojaei F, Saini SS. Somatic hypermutations and isotype restricted exceptionally long CDR3H contribute to antibody diversification in cattle. Vet Immunol Immunopathol. 2009 Jan 15;127(1-2):106-13. PMID: 19012969. Koti M, Kataeva G, Kaushik AK. Organization of D(H)-gene locus is distinct in cattle. Dev Biol (Basel). 2008;132:307-13. PMID: 18817318.